Latest news

Orchard Therapeutics, today announced the opening of a second facility for technical operations in the San Francisco Bay Area.

Orchard Therapeutics Limited, announces today that it has acquired an exclusive license to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B (or MPS-IIIB) from The University of Manchester, UK